As a whole, this study suggests that the molecular characterization of CD34+ cells from CALR-mutated and JAK2V617F-positive ET patients, could shed light on the signaling pathways deregulated in CALR-mutated patients and elucidate their contribution to typical features of these patients, such as high platelet count and low thrombotic risk. This evidence concerns the gene CALR and essential thrombocythemia.